New Therapy for Transthyretin-Associated Amyloidosis
AssigneeSOM Innovation Biotech, S.L.
InventorsMarc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
Life of this patent
Estimating the term…
Abstract
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Claims18
1-13. (canceled)
A method for treating transthyretin (TTR)-associated amyloidosis comprising administering to a subject in need thereof a therapeutically effective amount of at least one catechol-O-methyletransferase (COMT) inhibitor, wherein the TTR gene of the subject contains at least one mutation compared to the wild type TTR gene.
Dependencies are inferred from the claim text.